Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Restoring dependence

How Netris’ dependence receptor programs kill cancer stem cells missed by other drugs

Emily Cukier-Meisner, Senior Writer
August 19, 2017 1:12 AM UTC

Netris Pharma S.A.S. is aiming to boost rates and durations of responses to immunotherapies by targeting a population of slow-growing cells these therapies leave behind. The biotech’s mAbs restore the pro-apoptotic function of dependence receptors, and could be useful in combinations to root out slowly proliferating cancer stem cells.

By February, the company expects to have data from a Phase I trial of NP137 in solid tumors that will help determine the dose to take forward in combination studies...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Netris Pharma S.A.S.